#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Sickle cell disease Lip and/or oral cavity cancer Fibrodysplasia ossificans progressiva Osteopetrosis Stargardt's disease Acute hepatic failure Red blood cell abnormality Short stature Epilepsy Osteochondrodysplasia Oropharyngeal cancer recurrent Chondrodystrophy Head and neck cancer Pancreatic neuroendocrine tumour Breast cancer More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma refractory – Trials in Disease SAPHO syndrome – Basic Information Tuberous sclerosis complex – Life with Disease Immunodeficiency congenital – Life with Disease Toxic epidermal necrolysis Gaucher’s disease type III – Trials in Disease Phenylketonuria – Life with Disease Ehlers-Danlos syndrome – Basic Information Pulmonary sarcoidosis – Treatment Brain stem glioma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Adrc001 Histamine Hydrochloride Specific Nucleic Acid Sna-Xfsa ISPAGHULA HUSK Lsta1 Cetrorelix Vanglusagene Ensiparvovec Human Coagulation Factor Ix Remibrutinib LUTETIUM LU-177 ADX-038 Ngi226 Narsoplimab Lonapegsomatropin Ezabenlimab TAGRAXOFUSP Bepranemab GEN1078 Tinengotinib Dl-Alpha-Tocopherol More therapies…

    Learn about Your Condition

    Pulmonary alveolar haemorrhage Alveolar proteinosis Cleft lip and palate Dementia with Lewy bodies Glaucoma Aortic valve disease Endocrine disorder Rosai-Dorfman syndrome Paresis Pleomorphic liposarcoma Arterial stiffness Tonsillitis Urinary tract infection Liposarcoma recurrent Thyroid disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Human Albumin Solution and Ringer Lactate for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastases to peritoneum
    Investigated Drugs:
    • Human Albumin Solution
    • Mannitol
    France

  • Study Comparing Ivonescimab to FOLFOX Drug Combination for Patients with Advanced Biliary Tract Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Ivonescimab
    • Calcium Folinate
    • Calcium Levofolinate
    France

  • Study Comparing Amivantamab and Chemotherapy Versus Cetuximab and Chemotherapy for Patients with Advanced Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Amivantamab
    • Cetuximab
    Belgium France Germany Hungary Italy The Netherlands +3

  • Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

    Recruiting

    1 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Adenocarcinoma pancreas
    • Biliary neoplasm
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    Belgium France Germany Ireland Italy The Netherlands +3

  • Study on the Safety of Trifluridine/Tipiracil for Patients with Dihydropyrimidine Dehydrogenase Deficiency and Metastatic Colorectal or Gastroesophageal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    • Gastrooesophageal cancer
    Investigated Drugs:
    • Panitumumab
    • Tipiracil
    • Tipiracil Hydrochloride
    France

  • Study on Post-Operative Chemotherapy with Doxorubicin and Trabectedin for Patients with High-Risk Localized Uterine Leiomyosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Uterine leiomyosarcoma
    Investigated Drugs:
    • Trabectedin
    • Doxorubicin Hydrochloride
    France Spain

  • Study on Sequential Treatment with Gemcitabine, Paclitaxel, and FOLFIRINOX for Patients with Locally Advanced Pancreatic Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma
    Investigated Drugs:
    • Levoleucovorin
    • Fluorouracil
    • Gemcitabine
    France

  • Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    • Topotecan
    Austria Belgium Czechia France Germany Greece +7

  • Study on Early Erectile Rehabilitation with Sildenafil for Men After Rectal Cancer Surgery

    Recruiting

    3 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Sildenafil
    France

  • Study on Pravastatin for Patients with Severe Radio-Induced Breast Fibrosis After Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Pravastatin Sodium
    France
Previous Page
1 … 3 4 5 6 7 … 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!